NICE restricts NHS access to Alexion’s £366K-a-year bone drug
The National Institute for Health and Care Excellence has published draft guidelines that restrict the use of Alexion’s £366,912-a-year enzyme replacement therapy Strensiq by the National Health Service in treating patients with hypophosphatasia.
Read More
